## Diagnosis: Tuberculosis with Granulomatous Inflammation The clinical presentation of fever, weight loss, and a chronic ulcer with caseating granulomas and acid-fast bacilli is diagnostic of **tuberculosis**, a classic cause of granulomatous inflammation. ## First-Line Treatment Regimen **Key Point:** The standard first-line anti-tuberculosis regimen is a **4-drug combination** for the intensive phase (2 months), followed by a 2-drug maintenance phase (4 months). ### Intensive Phase (2 months) - **Isoniazid (INH)** — inhibits mycolic acid synthesis - **Rifampicin (RIF)** — inhibits bacterial RNA polymerase - **Pyrazinamide (PZA)** — active in acidic environment of macrophages - **Ethambutol (EMB)** — inhibits arabinosyl transferase ### Continuation Phase (4 months) - **Isoniazid + Rifampicin** alone ## Why This Combination? | Drug | Mechanism | Key Feature | |------|-----------|-------------| | INH | Inhibits mycolic acid synthesis | Bactericidal; most potent | | RIF | RNA polymerase inhibitor | Bactericidal; broad spectrum | | PZA | Active in acidic pH | Penetrates caseous necrosis | | EMB | Arabinosyl transferase inhibitor | Bacteriostatic; prevents resistance | **High-Yield:** The 4-drug regimen (HRZE) is essential to prevent **drug resistance**. Monotherapy or 2-drug regimens are inadequate and lead to treatment failure and MDR-TB. **Clinical Pearl:** Pyrazinamide is particularly important because it penetrates the acidic environment within caseous granulomas, where Mycobacterium tuberculosis resides in a semi-dormant state. **Mnemonic:** **RIPE** (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol) — the four-drug intensive phase.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.